Help Us Improve Our Site!
We are always trying to provide a better, more relevant website to meet the needs of our readers. The best way to do that ... Read more
Updates
-
-
Peroxiredoxin-4 May Be Useful Biomarker for Early Detection of Acute Exacerbations in IPF, Study Suggests
The protein peroxiredoxin-4 may be a useful blood marker in the early detection of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF), a study ... Read more -
It Takes a Village to Survive Pulmonary Fibrosis
You may be familiar with the proverb, “It takes a village to raise a child.” The phrase is believed to have originated from the ... Read more -
New Pulmonary Wellness Foundation Offers Free Online Rehab Programs
New York cardiopulmonary physical therapist Noah Greenspan has launched the Pulmonary Wellness Foundation (PWF), a nonprofit group that provides free online information on a ... Read more -
Caregivers Need Care, Too
I was recently brainstorming ideas with other rare disease columnists about how to support someone admitted for a long hospital stay. I started thinking ... Read more
-
Phase 2 Trial of Potential Oral Treatment for IPF Fully Enrolled, Galapagos Says
Galapagos NV announced that its Phase 2 PINTA trial, evaluating the safety and effectiveness of ... -
My Latest Health Setback Left Me Feeling Overwhelmed with Guilt
You would be hard-pressed to find anyone who hates pulmonary fibrosis (PF) more than ... -
In Its 10th Year, ‘Broadway Belts for PFF!’ Will Take Stage Feb. 24
Marking a decade of raising funds to battle pulmonary fibrosis (PF), this year’s glitzy and ... -
Boehringer Ingelheim Acquires Enleofen’s Anti-IL-11 Therapeutic Platform for Fibrotic Diseases
Boehringer Ingelheim has acquired the worldwide exclusive rights to Enleofen‘s interleukin-11 (IL-11) platform, designed ... -
Being Vulnerable with a Chronic Illness Can Be Beneficial
One of my most vivid memories of my late friend Serena Lawrence is when we ... -
Scholar Rock Receives $25M for Continued Research in Potential Therapies for Fibrotic Diseases
Biopharmaceutical company Scholar Rock received $25 million from Gilead Sciences to continue the development ...
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
Aloperine May Protect Against Pulmonary Fibrosis in Mouse Model, Study Suggests
News
Treatment with plant-derived aloperine reduces the severity of lung injury in a mouse model of pulmonary fibrosis, a new Chinese study reports. The research, “Aloperine Protects Mice against Bleomycin-induced Pulmonary Fibrosis by Attenuating Fibroblast Proliferation and Differentiation,” was published ... Read more